Hermetica Superfood Encyclopedia
The Short Answer
Vanadium Glycinate delivers vanadium chelated to glycine, enabling insulin-mimetic activity through phosphorylation of insulin receptor substrates, GLUT-4 translocation to cell membranes, and inhibition of protein tyrosine phosphatases that normally suppress insulin signaling. Human clinical evidence remains preliminary and is extrapolated primarily from vanadyl sulfate trials, where 100 mg/day (~31 mg elemental vanadium) improved insulin sensitivity and reduced fasting blood glucose in type 2 diabetic patients, with organic chelated forms hypothesized to offer up to 50% greater bioavailability over inorganic salts.
CategoryMineral
GroupMineral
Evidence LevelPreliminary
Primary Keywordvanadium glycinate benefits
Vanadium Glycinate — botanical close-up
Health Benefits
**Blood Glucose Regulation**
Vanadium's vanadyl (VO²⁺) ion mimics insulin by activating the insulin receptor tyrosine kinase cascade, promoting GLUT-4 translocation to skeletal muscle and adipocyte membranes, thereby increasing cellular glucose uptake without requiring endogenous insulin binding.
**Insulin Sensitivity Enhancement**
By inhibiting protein tyrosine phosphatases (PTPs) such as PTP1B, vanadium prolongs the phosphorylated, active state of the insulin receptor and its downstream substrates (IRS-1, IRS-2), amplifying insulin signaling in both hepatic and peripheral tissues.
**Glycogen Synthesis Support**
Vanadium activates glycogen synthase via the PI3K/Akt pathway, facilitating the conversion of circulating glucose into glycogen stores in liver and skeletal muscle, which may contribute to reduced postprandial hyperglycemia.
**Lipid Metabolism Modulation**
Vanadium compounds have demonstrated inhibition of lipolysis in adipocytes and reduced hepatic free fatty acid uptake in preclinical models, potentially lowering circulating triglycerides and supporting a more favorable lipid profile in insulin-resistant states.
**Enhanced Amino Acid and Glucose Transport in Muscle**
The glycinate chelate form, analogous to bis-glycinato oxovanadium (BGOV), is proposed to facilitate concurrent glucose and amino acid entry into muscle cells, a mechanism of interest to athletes and bodybuilders seeking improved nutrient partitioning.
**Antioxidant Activity**
Certain vanadium complexes exhibit reactive oxygen species (ROS) scavenging properties in vitro, potentially reducing oxidative stress associated with hyperglycemia, though this effect has not been confirmed in rigorous human trials for the glycinate form specifically.
**Potential Cardioprotective Effects**
Preclinical data suggest vanadium may reduce cardiac lipid accumulation and improve myocardial glucose utilization in diabetic animal models, though extrapolation to human cardiovascular outcomes requires substantially more investigation.
Origin & History
Natural habitat
Vanadium is a naturally occurring trace mineral found in soil, seawater, and certain foods including black pepper, shellfish, mushrooms, and parsley, with no single geographic center of abundance. It is not cultivated but rather extracted from mineral deposits worldwide, including significant reserves in China, Russia, and South Africa. The glycinate chelate form is a synthetic laboratory compound produced by complexing vanadyl ions (VO²⁺) with glycine amino acid ligands, a process developed and patented by Albion Laboratories in the latter decades of the 20th century.
“Vanadium has no documented role in ancient traditional medicine systems such as Ayurveda, Traditional Chinese Medicine, or European herbalism, as its biological significance was not recognized until the 20th century; the element itself was first isolated by Swedish chemist Nils Gabriel Sefström in 1830, named after the Norse goddess Vanadis (Freyja) for the varied colors of its compounds. Scientific interest in vanadium's metabolic effects began in earnest in the 1980s and early 1990s when researchers observed that inorganic vanadium salts lowered blood glucose in diabetic animal models, sparking investigation into its insulin-mimetic properties. The development of chelated organic forms, including BGOV and vanadium nicotinate glycinate, followed in the 1990s as pharmaceutical and nutraceutical scientists sought to improve bioavailability and reduce the gastrointestinal toxicity associated with inorganic salts; Albion Laboratories' patented amino acid chelation technology was central to this development. By the late 1990s and early 2000s, vanadium-containing supplements had gained popularity in bodybuilding and fitness communities based on claims of enhanced glucose and amino acid partitioning into muscle tissue, although these claims have never been substantiated by rigorous human clinical trials.”Traditional Medicine
Scientific Research
The clinical evidence base for vanadium glycinate as a distinct compound is sparse, with most human data derived from studies using inorganic vanadyl sulfate or sodium metavanadate in small, short-duration trials typically involving fewer than 30 participants with type 1 or type 2 diabetes. A small number of phase I/II human trials using vanadyl sulfate at 100 mg/day (~31 mg elemental vanadium) over 3–6 weeks demonstrated measurable reductions in fasting blood glucose and improved hepatic insulin sensitivity, as assessed by hyperinsulinemic-euglycemic clamp techniques, but these studies lacked placebo controls or were underpowered to detect meaningful effect sizes. Preclinical evidence in streptozotocin (STZ)-induced diabetic rat models is more extensive and consistently demonstrates improved glycemic control, GLUT-4 upregulation, and reduced hepatic gluconeogenesis across multiple vanadium compounds; the organic chelate BGOV (bis-glycinato oxovanadium) has been cited in animal literature as exhibiting approximately 50% greater efficacy than vanadyl sulfate at equivalent elemental vanadium doses. No large-scale randomized controlled trials (RCTs), meta-analyses, or systematic reviews specific to vanadium glycinate or BGOV in humans have been published as of current literature; the evidence tier is therefore classified as preliminary, and effect sizes, confidence intervals, and long-term safety data in humans remain undefined.
Preparation & Dosage
Traditional preparation
**Chelated Powder/Capsule (Vanadium Glycinate or Vanadium Nicotinate Glycinate)**
1–10 mg elemental vanadium per day for general supplemental use; start at the lowest effective dose to assess tolerance
**Vanadyl Sulfate (Reference Standard)**
100 mg/day vanadyl sulfate providing approximately 31 mg elemental vanadium has been used in human diabetes trials, representing the highest dose range with documented clinical monitoring; this dose should not be self-administered without medical supervision
**Therapeutic Range (Extrapolated)**
4–21 mg elemental vanadium) based on IDDM/NIDDM pilot study ranges; the glycinate chelate may permit lower elemental doses due to enhanced bioavailability
0.083–0.42 mmol elemental vanadium per day (approximately .
**Timing**
Taken with meals to improve gastrointestinal tolerance and to align absorption with postprandial glucose rises; split dosing (morning and evening) may reduce peak GI irritation.
**Standardization**
No pharmacopoeial standardization exists for vanadium glycinate supplements; quality products should specify elemental vanadium content per serving, not merely the chelate weight.
**Athletic/Performance Context**
5–10 mg elemental vanadium per day for nutrient partitioning purposes, though clinical evidence supporting this application is entirely absent
Bodybuilders have historically used .
**Duration**
Long-term continuous use is not established as safe; cycling protocols and periodic serum vanadium monitoring are recommended for any use exceeding 4–6 weeks.
Nutritional Profile
Vanadium Glycinate is a synthetic chelate compound and not a whole food; it contributes negligible macronutrients (carbohydrates, proteins, fats) at supplemental doses and is used exclusively as a micronutrient delivery vehicle for elemental vanadium. Vanadium itself is classified as an ultratrace mineral with no established Recommended Dietary Allowance (RDA) or Adequate Intake (AI) in the United States; typical dietary intake from food sources (seafood, mushrooms, cereals, black pepper) ranges from 6–18 micrograms per day, far below supplemental doses. The glycinate moiety contributes minimal amounts of the amino acid glycine, insufficient to confer independent nutritional benefit at standard supplement doses. Bioavailability of vanadium from food sources is estimated at 1–5%, while organic chelated forms are hypothesized to achieve significantly higher intestinal absorption—potentially 10–30%—through amino acid transporter-mediated uptake, though precise human pharmacokinetic data for vanadium glycinate specifically are not available in published literature.
How It Works
Mechanism of Action
Vanadium Glycinate releases vanadyl ions (VO²⁺) upon gastrointestinal absorption, which then enter systemic circulation and act as insulin mimetics by directly inhibiting protein tyrosine phosphatase 1B (PTP1B), the enzyme responsible for dephosphorylating and deactivating the insulin receptor, thereby sustaining insulin receptor substrate (IRS-1/IRS-2) phosphorylation downstream. This sustained phosphorylation activates phosphoinositide 3-kinase (PI3K) and its effector Akt (protein kinase B), triggering translocation of GLUT-4 glucose transporter vesicles to skeletal muscle and adipocyte plasma membranes, increasing glucose uptake independent of—or synergistically with—endogenous insulin. Vanadyl also activates glycogen synthase kinase pathways to promote hepatic and muscular glycogen synthesis while simultaneously inhibiting gluconeogenic enzymes, including phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase, reducing hepatic glucose output. The glycinate chelation is hypothesized to improve mucosal uptake via amino acid transporter-mediated intestinal absorption and to stabilize the vanadyl ion against premature oxidation to the less bioactive vanadate (VO₄³⁻) form, though direct pharmacokinetic data confirming this for vanadium glycinate specifically remain limited.
Clinical Evidence
Human clinical investigation into vanadium compounds for glycemic management has been limited to small exploratory trials, most involving vanadyl sulfate at doses of 0.083–0.42 mmol elemental vanadium per day administered to patients with type 2 (NIDDM) or insulin-dependent (IDDM) diabetes over periods of 3–8 weeks, with outcomes including fasting plasma glucose, HbA1c, and insulin sensitivity indices. These trials consistently reported directional improvements in blood glucose regulation and modest reductions in exogenous insulin requirements in IDDM patients, but were universally underpowered (n < 30) and lacked standardized placebo-controlled designs, limiting causal inference. No clinical trials have been conducted using vanadium glycinate or the BGOV chelate specifically in human subjects, meaning all extrapolations about its glucose-lowering efficacy in humans rest on mechanistic plausibility and animal model data rather than direct clinical proof. Given the narrow therapeutic index of vanadium and the absence of Phase III RCT data, clinical confidence in recommending vanadium glycinate for glycemic management remains low, and its use should be considered experimental pending adequately powered, controlled human trials.
Safety & Interactions
Vanadium exhibits a narrow therapeutic index; at supplemental doses of 1–10 mg elemental vanadium per day, gastrointestinal side effects including nausea, cramping, diarrhea, and green discoloration of the tongue are the most commonly reported adverse effects, while higher doses (>50 mg elemental vanadium) risk systemic toxicity affecting the liver, kidneys, nervous system, and cardiovascular system, including inhibition of coagulation cascades. The most clinically significant drug interaction is additive hypoglycemia when combined with antidiabetic medications (insulin, sulfonylureas, metformin, GLP-1 agonists), requiring blood glucose monitoring and potential dose adjustment; vanadium also possesses antiplatelet and anticoagulant properties that may potentiate the effects of warfarin, aspirin, clopidogrel, and other antithrombotic agents, increasing bleeding risk. Vanadium glycinate is contraindicated in individuals with pre-existing renal impairment (due to renal accumulation), known vanadium sensitivity, active clotting disorders, or those taking anticoagulant therapy; long-term high-dose use has demonstrated dose-dependent and time-dependent carcinogenic and organotoxic effects in animal models, and no safe upper limit for chronic human supplementation has been formally established by regulatory agencies. Pregnancy and lactation use is not recommended due to absence of safety data and evidence of embryotoxicity in animal studies; the maximum tolerable upper intake level suggested by some researchers is 1.8 mg elemental vanadium per day for healthy adults, well below the therapeutic doses studied in diabetes trials.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Bis-glycinato oxovanadium (BGOV)Vanadyl glycinateVanadium Nicotinate GlycinateChelated vanadiumVO²⁺-glycine complex
Frequently Asked Questions
What is vanadium glycinate used for?
Vanadium Glycinate is primarily used as a dietary supplement to support blood glucose regulation and insulin sensitivity, particularly in the context of type 2 diabetes management and athletic nutrient partitioning. It delivers vanadyl ions (VO²⁺) chelated to glycine, which act as insulin mimetics by inhibiting PTP1B and promoting GLUT-4 translocation to muscle and fat cell membranes, facilitating glucose uptake without requiring insulin to bind its receptor. Its use for these purposes remains experimental in humans, with most supporting evidence derived from animal models and small vanadyl sulfate trials.
How does vanadium glycinate differ from vanadyl sulfate?
Vanadyl sulfate is an inorganic vanadium salt that provides vanadyl ions but has relatively poor gastrointestinal bioavailability (estimated at 1–5%) and is more likely to cause GI side effects such as nausea and cramping at therapeutic doses. Vanadium Glycinate is an organic chelate in which vanadyl is bound to glycine amino acid ligands, hypothesized to improve intestinal absorption through amino acid transporter pathways and to reduce GI irritation, potentially offering up to 50% greater therapeutic effect per equivalent dose of elemental vanadium. However, direct head-to-head human pharmacokinetic comparisons between the two forms have not been published in peer-reviewed literature.
What dose of vanadium glycinate should I take for blood sugar support?
For general supplemental use, doses of 1–10 mg of elemental vanadium per day are most commonly referenced for vanadium-containing supplements, with users advised to start at the lowest end of this range to assess gastrointestinal tolerance. Therapeutic doses studied in human diabetes trials using vanadyl sulfate ranged from approximately 0.083–0.42 mmol elemental vanadium per day (roughly 4–21 mg) under medical supervision, representing a higher range that should not be self-administered without monitoring for hypoglycemia and toxicity. No dose has been formally approved or standardized for vanadium glycinate specifically, and long-term use at any dose without medical oversight is not advised given vanadium's narrow therapeutic index.
Is vanadium glycinate safe, and what are the side effects?
At low supplemental doses (1–10 mg elemental vanadium/day), the most common side effects are gastrointestinal in nature, including nausea, diarrhea, stomach cramping, and green discoloration of the tongue or stool due to vanadium's color properties. At higher doses or with chronic use, vanadium can accumulate and cause hepatic, renal, neurological, and cardiovascular toxicity; it also inhibits platelet aggregation and coagulation, raising bleeding risk especially in those on anticoagulant medications. Vanadium glycinate is not recommended for people with kidney disease, clotting disorders, or those taking blood sugar-lowering or blood-thinning medications without physician supervision, and its safety in pregnancy and lactation has not been established.
Does vanadium glycinate help with bodybuilding or athletic performance?
Vanadium supplements, including glycinate chelates, gained popularity in bodybuilding communities during the 1990s based on the hypothesis that insulin-mimetic activity would enhance glucose and amino acid uptake into skeletal muscle, improving nutrient partitioning, glycogen storage, and potentially muscle growth. While the molecular mechanism is biologically plausible—GLUT-4 translocation and enhanced amino acid transport in muscle tissue—no controlled clinical trials have demonstrated measurable improvements in body composition, strength, or athletic performance in healthy trained individuals. Current evidence does not support vanadium glycinate as an evidence-based ergogenic aid, and any potential benefit must be weighed against the risk of toxicity at the higher doses historically used in sports nutrition contexts.
Does vanadium glycinate interact with diabetes medications like metformin or insulin?
Vanadium glycinate may potentiate insulin-like effects and could theoretically enhance the glucose-lowering action of diabetes medications, increasing hypoglycemia risk. Anyone taking prescription diabetes medications should consult their healthcare provider before supplementing with vanadium glycinate, as dosage adjustments to medications may be necessary. Monitoring of blood glucose levels is recommended when combining vanadium with insulin or oral hypoglycemic agents.
Why is vanadium glycinate preferred over other vanadium forms for absorption?
Vanadium glycinate uses glycine as a chelating amino acid, which enhances intestinal absorption and improves bioavailability compared to inorganic vanadium salts like vanadyl sulfate. The glycine-bound form reduces gastrointestinal irritation and promotes transport via amino acid carriers in the intestinal epithelium. This chelation strategy results in better cellular uptake and potentially greater insulin-mimetic effects at lower doses.
Is vanadium glycinate safe for long-term supplementation, and are there cumulative toxicity concerns?
Vanadium can accumulate in bone and other tissues with chronic supplementation, raising theoretical concerns about long-term safety at elevated doses. Most safety data supports short- to medium-term use (weeks to a few months) at moderate doses, but limited human data exists on supplementation beyond 12 weeks. Periodic monitoring of kidney function and blood counts is prudent for individuals considering chronic vanadium supplementation, as excessive vanadium exposure is associated with nephrotoxicity and hematologic effects.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w vanadium-glycinate curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
